University of Chicago Medicine Comprehensive Cancer Center researchers have found a new treatment for advanced prostate cancer. They achieved complete tumor control and extended survival in a mouse model of prostate cancer using a three-drug regimen that targets PI3K, MEK, and Wnt/β-catenin signaling pathways. The intermittent dosing doesn’t cause long-term side effects, and a success rate of 100% was observed in the model.
News – Masimo reports cyber incident affecting production sites – teiss
Masimo has reported a cyber incident that has impacted its production sites. The company is currently assessing the situation to understand the extent of the
